| Literature DB >> 32807215 |
Karina Glick1, Irina Novofastovski2, Naama Schwartz3, Reuven Mader4.
Abstract
OBJECTIVE: To describe actual cardiovascular events over a decade in patients with diffuse idiopathic skeletal hyperostosis (DISH), without previously known CV diseases.Entities:
Keywords: Atherosclerosis; Cardiovascular disease; Diffuse idiopathic skeletal hyperostosis; Ischemic heart disease; Metabolic syndrome; Myocardial infarction
Mesh:
Year: 2020 PMID: 32807215 PMCID: PMC7430040 DOI: 10.1186/s13075-020-02278-w
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Characteristics of the DISH group and control
| DISH | Control | |||
|---|---|---|---|---|
| Age at 2006 | 64.02 (9.76, 63) | 62.13 (8.6, 60) | NS | |
| Age at 2016 | 73.87 (9.21, 73) | 72.21 (8.08, 71) | NS | |
| Men (%) | 13 (28.9%) | 11 (21.3%) | NS | |
| BMI at 2006 | 34.02 (6.24, 32) | 30.74 (5.02, 30) | 0.0069 | |
| Smokers 2006 | 13 (28.9%) | 16 (34.0%) | NS | |
| FRS calculated at 2006 | 28.67 (20.33, 23) | 17.85 (16.31, 12) | 0.0028 | |
| HTN | Systolic blood pressure 2006 mmHg | 141.51 (16.49, 141) | 132.09 (20.43, 129) | 0.0171 |
| Diastolic blood pressure 2006 mmHg | 82.06 (9.83, 82) | 80.13 (10.47, 78) | 0.0576 | |
| Total blood cholesterol | 2006 (mg/dl) (mean, SD) | 214.38 (38.98, 211) | 208.28 (35.95, 206) | NS |
| 2016 (mg/dl) (mean, SD) | 174.33 (40.1, 169) | 190.34 (38.32, 185) | NS | |
| HDL levels | 2006 (mg/dl) (mean, SD) | 51.2 (12.19, 48) | 51.81 (13.47, 49) | NS |
| 2016 (mg/dl) (mean, SD) | 47.51 (14.52, 44) | 51.26 (12.7, 48) | NS | |
| LDL levels | 2006 (mg/dl) (mean, SD) | 128.07 (33.78, 132) | 126.34 (30.21, 129) | NS |
| 2016 (mg/dl) (mean, SD) | 102.88 (30.87, 101) | 111.66 (34.59, 113) | NS | |
| HbA1c levels | 2006 mg% (mean, SD) | 6.35 (0.98, 6) | 5.73 (0.44, 5.7) | 0.0004 |
| 2016 mg% (mean, SD) | 6.51 (0.99, 6.3) | 5.9 (1.16, 5.7) | 0.0005 | |
BMI body mass index, FRS Framingham risk score, according to the overall CVD risk [11], HTN hypertension, HDL high-density lipoprotein, LDL low-density lipoprotein, HbA1c glycated hemoglobin
Fig. 1Composite outcome prediction of the Framingham risk score
Concomitant diagnoses and medications at 2006 and during follow-up
| DISH | Control | |||
|---|---|---|---|---|
| Dyslipidemia | 2006 | (48.9) 22 | (29.8) 14 | 0.06 |
| 2016 N (%) | (81.1) 36 | (69.6) 32 | 0.176 | |
| HTN | 2006 | (62.2) 28 | (38.3) 18 | 0.02 |
| 2016 | (86.7) 39 | (59.6) 28 | 0.003 | |
| Type 2 DM | 2006 | (33.3) 15 | (8.5) 4 | 0.003 |
| 2016 | (59.1) 26 | (17) 8 | < 0.0001 | |
| Heart failure (HFrEF + HFpEF) | 2006 | 0 (0) | 0 (0) | |
| 2016 | 13 (28.9) | 12 (25.5) | 0.717 | |
| Aspirin treatment | 2006 | (35.6) 16 | (19.2) 9 | 0.077 |
| 2016 | (60) 27 | (44.7) 21 | 0.598 | |
| ACEi/ARB treatment | 2006 | (31.1) 14 | (14.9) 7 | 0.063 |
| 2016 | (62.2) 28 | (27.7) 13 | 0.0009 | |
| HMG-CoA reductase inhibitor treatment | 2006 | (40) 18 | (25.5) 12 | 0.138 |
| 2016 | (75) 33 | (51.1) 24 | 0.0185 | |
| Metformin treatment | 2006 | 10 (22.2) | 3 (6.4) | 0.029 |
| 2016 | 12 (26.7) | 4 (8.5) | 0.021 |
HFrEF heart failure with reduced ejection fraction, HFpEF heart failure with preserved ejection fraction, ACEi/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blocker
Cardiovascular outcomes during the 10-year follow-up
| DISH | Control | ||
|---|---|---|---|
| Myocardial infarction | 11 (24.4) | 2 (4.3) | 0.0055 |
| Transient ischemic attack | 5 (11.1) | 9 (19.2) | 0.2833 |
| Cerebrovascular accident | 4 (8.9) | 2 (4.3) | 0.4297 |
| Peripheral vascular disease | 1 (2.2) | 0 (0) | 0.4891 |
| Heart failure with reduced ejection fraction | 3 (6.7) | 0 | 0.1130 |
| All-cause mortality | 5 (11.1) | 4 (8.5%) | 0.7369 |
| CV mortality | 3 (6.7) | 0 (0%) | 0.1130 |
| Composite outcomes* | 17 (38.8) | 12 (25.5) | 0.2063 |
*A subject with an outcome was counted once, even if had more than one outcome during the follow-up. P value calculated by the chi-square test (or Fisher’s exact test—depending on the percent of cells with an expected count less than 5)